These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells. Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670 [TBL] [Abstract][Full Text] [Related]
10. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339 [TBL] [Abstract][Full Text] [Related]
11. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941 [TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells. Handgretinger R; Kimmig A; Lang P; Daurer B; Kuci S; Bruchelt G; Treuner J; Niethammer D Nat Immun Cell Growth Regul; 1989; 8(4):189-96. PubMed ID: 2507905 [TBL] [Abstract][Full Text] [Related]
13. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects]. Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581 [TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related]
15. Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma. Chao TY; Ohnishi H; Chu TM Immunology; 1990 May; 70(1):116-20. PubMed ID: 2113034 [TBL] [Abstract][Full Text] [Related]
16. The role of interferon-gamma in the immunotherapy of neuroblastoma. Handgretinger R; Bruchelt G; Daurer B; Lang P; Herter M; Dopfer R; Müller B; Reisfeld RA; Treuner J; Niethammer D Prog Clin Biol Res; 1991; 366():401-7. PubMed ID: 1906184 [No Abstract] [Full Text] [Related]
17. Immune-mediated regression of 'metastatic' neuroblastoma in the liver. Ishizu H; Bove KE; Ziegler MM; Arya G J Pediatr Surg; 1994 Feb; 29(2):155-9; discussion 159-60. PubMed ID: 8176585 [TBL] [Abstract][Full Text] [Related]
18. Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapy. Fowler CL; Brooks SP; Squire R; Rich GA; Rossman JE; Finegold MJ; Allen JE; Cooney DR J Pediatr Surg; 1991 Apr; 26(4):381-7; discussion 387-8. PubMed ID: 2056397 [TBL] [Abstract][Full Text] [Related]
19. [A novel experimental approach to immunotherapy against malignant brain tumor with the mouse IFN-gamma gene transfer]. Nishihara K Nihon Geka Hokan; 1989 Jan; 58(1):18-42. PubMed ID: 2508589 [TBL] [Abstract][Full Text] [Related]